A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults

This is a single-center, open-label, fixed sequence, Phase 1 study in healthy adult
participants to study the effects of itraconazole and rifampicin on the pharmacokinetics,
safety, and tolerability of a single dose of JNJ-53718678. This study will be conducted in 2
separate panels, with 14 participants in Panel 1 and 16 participants in Panel 2. The study
consists of following phases: Screening (28 days), Treatment phase (11 days) and Follow-up
(10 to 14 days after the last study drug intake). Blood samples will be collected for
evaluation of pharmacokinetics at pre-dose and post-dose of study treatment. Participants
will be assessed for safety and tolerability throughout the study.

Inclusion Criteria:

- Female participants must have a negative serum beta human chorionic gonadotropin
(beta hCG) pregnancy test at Screening

- At Screening, a female participant must be of non-childbearing potential

- Participant must have a Body Mass Index (BMI; weight in kilogram (kg) divided by the
square of height in meters) of 18.0 to 30.0 kilogram per meter square (kg/m2),
extremes included

- Participant must have a blood pressure (after the participant is supine for 5
minutes) between 90 and 140 millimeters of mercury (mmHg) systolic, inclusive, and
not higher than 90 mm Hg diastolic

- Participants must be healthy on the basis of a medical evaluation that reveals the
absence of any clinically relevant abnormality and includes a physical examination
(including height and body weight measurement and skin examination), medical history,
vital signs, and the results of blood biochemistry, blood coagulation, and hematology
tests, and a urinalysis performed at Screening

Exclusion Criteria:

- Participant with a history of or current clinically significant medical illness
including (but not limited to) cardiac arrhythmias or other cardiac disease,
hematologic disease, coagulation disorders, lipid abnormalities, significant
pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus,
hepatic insufficiency, renal dysfunction, thyroid disease, neurologic or psychiatric
disease, infection, or any other illness that the Investigator considers should
exclude the participant or that could interfere with the interpretation of the study
results

- Participants with abnormal values for alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) (greater than [>]1.00 * upper limit of laboratory normal range
[ULN])

- Participants with lack of good/reasonable venous access

- Participants with a past history of heart arrhythmias (extrasystoli, tachycardia at
rest) or, history of risk factors for Torsade de Pointes syndrome (example -
hypokalemia, family history of long QT Syndrome)

- Participants with any history of clinically significant skin disease such as, but not
limited to, dermatitis, eczema, drug rash, psoriasis, food allergy, and urticaria